白云山最新公告：子公司胞磷胆碱钠注射液获药品补充申请批准

证券之星08-19 17:52

白云山(600332.SH)公告称，公司控股子公司天心制药收到国家药监局核准签发的胞磷胆碱钠注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价，并同意增加4ml:0.5g规格。该药用于急性颅脑外伤及脑手术后的意识障碍，2025年国内销售额为8031万元，天心制药该药品销售收入为165.04万元，已投入研发费用约256.74万元。

以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2660944150?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-19 17:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660944150","market":"fut","top_or_hot":-1,"title":"白云山最新公告：子公司胞磷胆碱钠注射液获药品补充申请批准","media":"证券之星","content":"<html><body><p><a href=\"https://laohu8.com/S/600332\">白云山</a>(600332.SH)公告称，公司控股子公司天心制药收到国家药监局核准签发的胞磷胆碱钠注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价，并同意增加4ml:0.5g规格。该药用于急性颅脑外伤及脑手术后的意识障碍，2025年国内销售额为8031万元，天心制药该药品销售收入为165.04万元，已投入研发费用约256.74万元。</p><p>以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>白云山最新公告：子公司胞磷胆碱钠注射液获药品补充申请批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n白云山最新公告：子公司胞磷胆碱钠注射液获药品补充申请批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-19 17:52 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026081900030844.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>白云山(600332.SH)公告称，公司控股子公司天心制药收到国家药监局核准签发的胞磷胆碱钠注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价，并同意增加4ml:0.5g规格。该药用于急性颅脑外伤及脑手术后的意识障碍，2025年国内销售额为8031万元，天心制药该药品销售收入为165.04万元，已投入研发费用约256.74万元。以上内容为证券之星据公开信息整理，仅供参考不构成...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026081900030844.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1606","symbol_name":"中医药概念","start_time":0,"source_url":"https://stock.stockstar.com/RB2026081900030844.shtml","article_id":"2660944150","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660944150","pubTimestamp":1787133174,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"白云山(600332.SH)公告称，公司控股子公司天心制药收到国家药监局核准签发的胞磷胆碱钠注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价，并同意增加4ml:0.5g规格。该药用于急性颅脑外伤及脑手术后的意识障碍，2025年国内销售额为8031万元，天心制药该药品销售收入为165.04万元，已投入研发费用约256.74万元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600332":"白云山","BK1606":"中医药概念","BK0012":"证金概念","BK0188":"融资融券","BK0196":"行业龙头","BK0175":"白马股","BK1521":"挪威政府全球养老基金持仓","BK0070":"员工持股","BK0097":"医药电商","BK0239":"医药制造","BK0028":"国家队","BK1197":"保健护理产品经销商","BK0183":"MSCI概念","BK1515":"抗疫概念","BK0096":"民营医院","00874":"白云山","BK1191":"制药"},"translate_title":"Baiyunshan's latest announcement: Subsidiary Citicoline Sodium Injection was approved for drug supplementary application","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":1.5,"00874":1.5},"content_text":"白云山(600332.SH)公告称，公司控股子公司天心制药收到国家药监局核准签发的胞磷胆碱钠注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价，并同意增加4ml:0.5g规格。该药用于急性颅脑外伤及脑手术后的意识障碍，2025年国内销售额为8031万元，天心制药该药品销售收入为165.04万元，已投入研发费用约256.74万元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660944150","isCrawlerRequest":true}